Pro DSLRs Lose Value More Slowly Than Consumer Ones, Study Finds
New cameras are like new computers. Both of them depreciate quite quickly as new technologies and new models are churned out year after year. This presents a perpetual problem for photographers, as many constantly grapple with the question of whether to upgrade their camera to a more recent model, or whether to purchase a higher-end model so that it keeps its value longer.
Market research software company Terapeak recently did a study that looks at depreciation in Canon EOS DSLRs. The results are pretty interesting.
The chart above is an apples to apples comparison of depreciation for four Canon models released over the past year: the Canon 1D X (MSRP: $6,799), the Canon 5D Mk III (MSRP: $3,499), the Canon 6D (MSRP: $2,099), and the Canon 650D (MSRP: $850).
This is the same comparison graph with some trend lines added in:
Here’s what the study discovered: cheaper cameras do indeed depreciate faster than more expensive models.
High end cameras such as the 1D X and 5D Mk3 depreciate at roughly the same rate (i.e. they both hold their values relatively well), even though one model is much more expensive than the other (the former is double the price of the latter).
For some reason, even though the full frame 6D is billed as a prosumer camera that sits alongside the 5D Mark II and Mark III, it depreciates at roughly the same rate as the entry-level 650D.
After 26 weeks after being launched, the 1D X and 5D Mark III are still worth about 90% of their original market price, but the 6D and 650D have plummeted down to around 70% of their original values.
The key takeaways of these findings are: (1) purchasing a more expensive and higher-tier camera doesn’t ensure that the body will depreciate more slowly, and (2) purchasing a higher class of camera (pro versus amateur) is the way to go if you’d like to have a camera that keeps its value for a longer period of time.
For a closer look at how this study was conducted and the results that it came to, check out the reports on the Terapeak blog here and here.